COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Retrospectively registered

Titles & IDs
Public title
Anaesthesia practice since introduction of sugammadex: has it changed patient outcome?
Scientific title
Patient outcome after reversal of residual neuromuscular blockade with either neostigmine or no reversal agent vs. reversal with sugammadex.
Secondary ID [1] 279674 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Residual neuromuscular blockade, its reversal and associated patient outcome 285495 0
Condition category
Condition code
Anaesthesiology 285682 285682 0 0

Study type
Patient registry
Target follow-up duration
Target follow-up type
Description of intervention(s) / exposure
This is an observational trial.
We aim to retrospectively investigate outcome parameters (incidence of pulmonary complications postoperatively, length of stay in the recovery room/the hospital) and incidence of adverse airway events in the recovery room) in postoperative patients who received reversal of neuromuscular paralysis with either neostigmine or no reversal agent or sugammadex.

Data will be collected from patients' medical records, an electronic theatre management system (e.g. anaesthesia times, length of stay) and an electronic medical results system (ISOFT; e.g. white cell count and chest-xray reports). Data collection will include patients whose surgery took place from 1.3.11 until present. Data collection will include consecutive patients until the sample size per group has been achieved.
Intervention code [1] 283964 0
Not applicable
Comparator / control treatment
Both, reversal with neostigmine or the administration of no reversal agent will serve as (combined) "control"
Control group

Primary outcome [1] 286221 0
Incidence of postoperative pulmonary complications within 30 days (assessed via an electronic record keeping software ,ISOFT, which allows access to patients' chest xray reports). In addition, we will investigate patients' medical records to see whether any clinical signs of adverse pulmonary outcome (e.g. coughing, increased oxygen demand) where observed postoperatively.
Timepoint [1] 286221 0
within 30 days post operation (data assessed post-hoc = from medical records [pelectronic/paper] after at least 30 days from surgery)
Secondary outcome [1] 295407 0
length of stay in the recovery room/the hospital (assessed via both electronic and paper medical records in which the outcome parameters are automatically recorded).
Timepoint [1] 295407 0
at any time during the study period, but at least 30 days after a patients operation
Secondary outcome [2] 295408 0
adverse airway events (oxygen desaturation, need for anaesthetist airway review/ventilation, respiratory arrest)
Timepoint [2] 295408 0
at least 30 days after surgery (via electronic/paper medical records)

Key inclusion criteria
Patients operated at Royal Perth Hospital and tracheally intubated with the use of a neuromuscular blocking agent. Hereby the reason for the operation (= original medical condition leading to treatment) is unimportant
Minimum age
16 Years
Maximum age
100 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Patients with significant multi-trauma, cardiothoracic surgery and patients who arrive in or leave theatres intubated

Study design
Natural history
Convenience sample
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 284460 0
Self funded/Unfunded
Name [1] 284460 0
Thomas Ledowski
Address [1] 284460 0
Dept. of Anaesthesia
Royal Perth Hospital
Wellington Street
Perth WA 6000
Country [1] 284460 0
Primary sponsor type
Thomas Ledowski
Dept. of Anaesthesia
Royal Perth Hospital
Wellington Street
Perth WA 6000
Secondary sponsor category [1] 283386 0
Name [1] 283386 0
Address [1] 283386 0
Country [1] 283386 0

Ethics approval
Ethics application status
Ethics committee name [1] 286436 0
Human Ethics committee of the Royal Perth Hospital
Ethics committee address [1] 286436 0
Royal Perth Hospital
Colonial House
Murray Street
Perth WA 6000
Ethics committee country [1] 286436 0
Date submitted for ethics approval [1] 286436 0
Approval date [1] 286436 0
Ethics approval number [1] 286436 0

Brief summary
The drug sugammadex (Bridion) has recently been introduced into clinical practice at the Royal Perth Hospital (RPH). This drug provides the anaesthetist with a new and very efficient way of reversing the effects of amino-steroidal neuromuscular blocking agents.
If not completely reversed, the residual effects of muscle relaxants are known to significantly impair postoperative patient outcome (Murphy et al. , Anesthesia and Analgesia 2010; 111: 120-8).
Unfortunately, when muscle relaxants are either not reversed or neostigmine is used, the incidence of such residual paralysis is extremely high (50-60% at RPH 2011, own pilot data)! This is at least partially due to a lack of appropriate monitors (already highlighted this matter to hospital and monitors are being bought) but also the lack of a reliable muscle relaxant antagonist. The latter may have changed since introduction of sugammadex in Australia in 2010.

In a just completed audit we found strong evidence for a potential of sugammadex to result in better postoperative outcomes (lower incidence of residual neuromuscular blockade and lower incidence of postoperative pneumonia/atelectasis). However, the numbers investigated were too low to draw final conclusions. Based on this pilot data we will need to investigate at least 721 cases with the use of sugammadex and compare them with at least 721 control cases in whom no or a different reversal drug (neostigmine) has been used. This equals the investigation of data from patients intubated at RPH over approx. 12 months.

The goal of this retrospective study is to build on our previous audit and investigate whether the use of sugammadex indeed resulted in beneficial patient outcomes over the last 12 months.

For this purpose, the data review will identify all eligible patients who received neuromuscular blocking agents and the mode of its reversal at the end of surgery. Main outcome data are adverse events in the recovery room, within 30 days after surgery (lung associated complications) and length of stay (recovery/hospital).
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 33588 0
Address 33588 0
Country 33588 0
Phone 33588 0
Fax 33588 0
Email 33588 0
Contact person for public queries
Name 16835 0
Prof. Thomas Ledowski
Address 16835 0
Depot. of Anaesthesia
Royal Perth Hospital
Perth WA 6000
Country 16835 0
Phone 16835 0
0061 8 9224 1037
Fax 16835 0
Email 16835 0
Contact person for scientific queries
Name 7763 0
Prof. Thomas Ledowski
Address 7763 0
Depot. of Anaesthesia
Royal Perth Hospital
Perth WA 6000
Country 7763 0
Phone 7763 0
0061 8 9224 1037
Fax 7763 0
Email 7763 0

No information has been provided regarding IPD availability
Summary results
No Results